IP Library Granted Patent US 10,111,984
Granted Patent B2
US 10,111,984 · App. 15/284,657 · Granted Oct 30, 2018

Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation

Inventors: Karina Heredia Guillen (Santa Barbara, CA); Ahmet Tezel (Fort Worth, TX)
Assignee: Allergan, Inc.
A61L27/26A61K47/36A61K47/42A61L27/20A61L27/24A61L27/52A61L27/54A61L2300/402A61L2300/404A61L2300/41A61L2300/426A61L2300/43A61L2300/434A61L2300/442
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,111,984
App. No.
15/284,657
Granted
Oct 30, 2018
Kind
B2
Abstract

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Claims (24)

1. An injectable dermal filler, comprising:

a hydrogel comprising a hyaluronic acid polymer crosslinked with collagen via a zero-length crosslinking agent;

wherein said hydrogel is prepared by:

(a) reacting said hyaluronic acid polymer with said collagen via said zero-length cross-linking agent, thereby providing a crosslinked hyaluronic acid/collagen-based composition; and

(b) sterilizing the crosslinked hyaluronic acid/collagen-based composition via irradiation with ultraviolet light or a combination of ultraviolet and visible light.

2. The dermal filler of claim 1 , wherein the sterilizing is via irradiation with a combination of ultraviolet and visible light.

3. The dermal filler of claim 1 , wherein the sterilizing is via irradiation with ultraviolet light.

4. The dermal filler of claim 1 , wherein said zero-length cross-linking agent is a carbodiimide.

5. The dermal filler of claim 4 , wherein the carbodiimide is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).

6. The dermal filler of claim 4 , wherein said zero-length cross-linking agent is reacted with said hyaluronic acid polymer and said collagen in the presence of N-hydroxysuccinimide (NHS), sulfo-NHS or 4-dimethylaminopyridine (DMAP).

7. The dermal filler of claim 1 , wherein said zero-length cross-linking agent is reacted with said hyaluronic acid polymer and said collagen at a pH of between about 6.0 and about 8.0.

8. The dermal filler composition of claim 7 , wherein said pH is between about 6.5 and about 7.5.

9. The dermal filler of claim 7 , wherein said pH is about 7.0.

10. The dermal filler of claim 1 , having a hyaluronic acid concentration of at least 10 mg/mL.

11. The dermal filler of claim 1 , having a hyaluronic acid concentration of about 15 mg/mL to about 80 mg/mL.

12. The dermal filler of claim 1 , having a hyaluronic acid concentration of about 15 mg/mL to about 30 mg/mL.

13. The dermal filler composition of claim 1 , further comprising an active agent selected from the group consisting of an enzyme inhibitor, anesthetic agent, medicinal neurotoxin, antioxidant, anti-infective agent, anti-inflammatory agent, hormone, immunosuppressant and combinations thereof.

14. The dermal filler of claim 13 , wherein the active agent is an anesthetic agent.

15. The dermal filler of claim 14 , wherein the anesthetic agent is lidocaine.

16. The dermal filler of claim 15 , wherein the lidocaine is present at a concentration of between about 0.1% and about 5% by weight of the composition.

17. The dermal filler of claim 15 , wherein the lidocaine is present at a concentration of between about 0.2% to about 1.0% by weight of the composition.

18. The dermal filler of claim 15 , wherein the lidocaine is present at a concentration of about 0.3% by weight of the composition.

19. The dermal filler of claim 1 , further comprising uncrosslinked hyaluronic acid.

20. The dermal filler of claim 1 , having an elastic modulus (G′) of at least about 50 Pa.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2017
From: GUILLEN, KARINA HEREDIA; TEZEL, AHMET
To: ALERGAN, INC.
Reel/Frame 042433/0800 →
Continuity (5)
Continuation 14665820 · Mar 23, 2015
Continuation 14219652 · Mar 19, 2014
Division 13052690 · Mar 21, 2011
Provisional Application 61316283 · Mar 22, 2010
Related Publication 20170021057A1 · Jan 26, 2017